Parameter
| Biomarker | PAI-1 | Full name | Plasminogen activator inhibitor-1 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | 43 kDa | Core Functional Dimensions | Prognosis, therapeutic targets | |
| Disease | Angiosarcoma | Disease Subtypes | / | ||
| Organ | Tumor cells, endothelial cells, hepatocytes | Test Sample / Technology Platform | Organization/serum (IHC, ELISA) | ||
| Pathobiological Mechanisms | Promote angiogenesis, immune suppression and tumor microenvironment remodeling | ||||
| Clinical Availability Status | Cutting-edge research: inhibitors in clinical trials | ||||
| Notes and Dynamics | And SASP factor synergy, TM5614 joint nivolumab in resistance against PD-1 AS effective | ||||